Hunan Jiudian Pharmaceutical Co Ltd
Hunan Jiudian Pharmaceutical Co., Ltd. researches, develops, produces, and sells pharmaceutical products in China and internationally. Its products portfolio includes Pantoprazole Sodium Enteric-coated, Ferrous Succinate, Rosuvastatin Calcium, Ebastine, and Rabeprazole Sodium Enteric-coated Tablets; and Acetylcysteine Granules, Potassium Sodium Hydrogen Citrate Granules, Loxoprofen Sodium Gel Pat… Read more
Hunan Jiudian Pharmaceutical Co Ltd (300705) - Net Assets
Latest net assets as of September 2025: CN¥2.66 Billion CNY
Based on the latest financial reports, Hunan Jiudian Pharmaceutical Co Ltd (300705) has net assets worth CN¥2.66 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥3.67 Billion) and total liabilities (CN¥1.02 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.66 Billion |
| % of Total Assets | 72.34% |
| Annual Growth Rate | 27.41% |
| 5-Year Change | 202.36% |
| 10-Year Change | 892.79% |
| Growth Volatility | 25.71 |
Hunan Jiudian Pharmaceutical Co Ltd - Net Assets Trend (2013–2024)
This chart illustrates how Hunan Jiudian Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Hunan Jiudian Pharmaceutical Co Ltd (2013–2024)
The table below shows the annual net assets of Hunan Jiudian Pharmaceutical Co Ltd from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.53 Billion | +28.05% |
| 2023-12-31 | CN¥1.97 Billion | +27.09% |
| 2022-12-31 | CN¥1.55 Billion | +41.23% |
| 2021-12-31 | CN¥1.10 Billion | +31.55% |
| 2020-12-31 | CN¥835.68 Million | +9.69% |
| 2019-12-31 | CN¥761.87 Million | +6.09% |
| 2018-12-31 | CN¥718.16 Million | +8.77% |
| 2017-12-31 | CN¥660.26 Million | +104.14% |
| 2016-12-31 | CN¥323.43 Million | +27.08% |
| 2015-12-31 | CN¥254.51 Million | +21.27% |
| 2014-12-31 | CN¥209.87 Million | +19.34% |
| 2013-12-31 | CN¥175.85 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Hunan Jiudian Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1473.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.25 Billion | 49.38% |
| Common Stock | CN¥496.19 Million | 19.64% |
| Other Comprehensive Income | CN¥245.00 Million | 9.70% |
| Other Components | CN¥537.77 Million | 21.28% |
| Total Equity | CN¥2.53 Billion | 100.00% |
Hunan Jiudian Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Hunan Jiudian Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Wuxi Hodgen Technology Co Ltd
SHE:300279
|
$533.35 Million |
|
Guangdong Qunxing Toys Joint-Stock Co Ltd
SHE:002575
|
$533.55 Million |
|
Shandong Nanshan Zhishang Sci-Tech Co.Ltd.
SHE:300918
|
$533.64 Million |
|
Aucma Co Ltd
SHG:600336
|
$533.69 Million |
|
FORWARD AIR CORP. DL-01
F:FA2
|
$532.93 Million |
|
Semrush Holdings Inc
NYSE:SEMR
|
$532.89 Million |
|
Zhuhai Enpower Electric Co Ltd
SHE:300681
|
$532.89 Million |
|
Hunan Aerospace Huanyu Communication Technology Co. Ltd. A
SHG:688523
|
$532.84 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hunan Jiudian Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,973,269,899 to 2,526,729,860, a change of 553,459,961 (28.0%).
- Net income of 512,377,177 contributed positively to equity growth.
- Dividend payments of 115,711,143 reduced retained earnings.
- Other comprehensive income decreased equity by 2,725,170.
- Other factors increased equity by 159,519,097.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥512.38 Million | +20.28% |
| Dividends Paid | CN¥115.71 Million | -4.58% |
| Other Comprehensive Income | CN¥-2.73 Million | -0.11% |
| Other Changes | CN¥159.52 Million | +6.31% |
| Total Change | CN¥- | 28.05% |
Book Value vs Market Value Analysis
This analysis compares Hunan Jiudian Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.89x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 26.61x to 2.89x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | CN¥0.56 | CN¥14.83 | x |
| 2014-12-31 | CN¥1.59 | CN¥14.83 | x |
| 2015-12-31 | CN¥1.12 | CN¥14.83 | x |
| 2016-12-31 | CN¥1.33 | CN¥14.83 | x |
| 2017-12-31 | CN¥2.48 | CN¥14.83 | x |
| 2018-12-31 | CN¥2.21 | CN¥14.83 | x |
| 2019-12-31 | CN¥2.32 | CN¥14.83 | x |
| 2020-12-31 | CN¥2.54 | CN¥14.83 | x |
| 2021-12-31 | CN¥3.35 | CN¥14.83 | x |
| 2022-12-31 | CN¥3.97 | CN¥14.83 | x |
| 2023-12-31 | CN¥5.72 | CN¥14.83 | x |
| 2024-12-31 | CN¥5.13 | CN¥14.83 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hunan Jiudian Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 20.28%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 17.48%
- • Asset Turnover: 0.87x
- • Equity Multiplier: 1.33x
- Recent ROE (20.28%) is above the historical average (15.59%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 20.61% | 15.02% | 0.96x | 1.43x | CN¥18.66 Million |
| 2014 | 19.65% | 15.47% | 0.99x | 1.28x | CN¥20.25 Million |
| 2015 | 17.54% | 15.37% | 0.91x | 1.25x | CN¥19.19 Million |
| 2016 | 16.86% | 14.49% | 0.95x | 1.23x | CN¥22.18 Million |
| 2017 | 10.39% | 12.83% | 0.69x | 1.17x | CN¥2.55 Million |
| 2018 | 10.02% | 8.98% | 0.85x | 1.31x | CN¥169.08K |
| 2019 | 7.23% | 5.96% | 0.86x | 1.41x | CN¥-21.12 Million |
| 2020 | 9.84% | 8.41% | 0.87x | 1.35x | CN¥-1.31 Million |
| 2021 | 18.58% | 12.55% | 0.93x | 1.59x | CN¥94.31 Million |
| 2022 | 17.37% | 11.59% | 1.01x | 1.48x | CN¥114.44 Million |
| 2023 | 18.66% | 13.68% | 0.94x | 1.46x | CN¥170.93 Million |
| 2024 | 20.28% | 17.48% | 0.87x | 1.33x | CN¥259.70 Million |
Industry Comparison
This section compares Hunan Jiudian Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $5,061,893,866
- Average return on equity (ROE) among peers: 4.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hunan Jiudian Pharmaceutical Co Ltd (300705) | CN¥2.66 Billion | 20.61% | 0.38x | $533.22 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $2.84 Billion | -41.97% | 9.13x | $608.50 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.29 Billion | 4.72% | 1.33x | $324.94 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $11.33 Billion | 18.40% | 0.22x | $3.03 Billion |
| Wedge Industrial Co Ltd (000534) | $1.30 Billion | 13.53% | 1.39x | $1.92 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $525.21 Million | 17.84% | 0.75x | $5.59 Billion |
| Hainan Haiyao Co Ltd (000566) | $4.63 Billion | -3.44% | 1.33x | $704.71 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $268.78 Million | 10.37% | 0.50x | $325.99 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $2.07 Billion | 2.59% | 1.71x | $425.60 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $22.44 Billion | 6.25% | 0.15x | $2.04 Billion |
| Renhe Pharmacy Co Ltd (000650) | $3.91 Billion | 12.94% | 0.18x | $777.45 Million |